
David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

Your AI-Trained Oncology Knowledge Connection!


David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), a 2017 Giant of Cancer Care® in Lung Cancer, discusses the idea for an online treatment decision tool for lung cancer.

Published: September 27th 2018 | Updated: